Platelet Transfusions in Patients with Hypoproliferative Thrombocytopenia: Conclusions from Clinical Trials and Current Controversies.
Patients with hematologic malignancies frequently become thrombocytopenic as a result of their underlying malignancy or treatments, including cytotoxic chemotherapy and hematopoietic stem cell transplantation and are at increased risk of hemorrhage. Prophylactic platelet transfusions are aimed at preventing severe or life-threatening hemorrhage. This review summarizes recent evidence, including the need for prophylactic platelet transfusions, the optimal dose, platelet transfusion triggers, and risk factors for bleeding. It also discusses controversies surrounding platelet transfusions in this population.